AstraZeneca and Bristol Myers Squibb in $400 Billion Merger Talks

SentiSense · Published · Updated

AstraZeneca is in talks with Bristol Myers Squibb for a potential $400 billion merger. The deal could create a significant pharmaceutical presence. An...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis